high
Buy
6,000 shares
$44,400
Significance
6/10
CEO Frohlich buys 6,000 shares of JBIO at $7.40; first holding post-IPO at recently-listed company with $-2.5M net income
Tom Frohlich, Chief Executive Officer of Jade Biosciences, purchased 6,000 shares at $7.40 on 2025-05-16, establishing his first position in the company just 15 trading days after the recent listing. The purchase occurred at a company with a $-2.5M net income in its most recent fiscal year, indicating material unprofitability. The transaction value of $44,400.00 and the CEO's initial entry into ownership during the early post-IPO phase warrant investor attention to both the leadership's personal capital commitment and the company's near-term operational trajectory.